Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Chubb
Cerilliant
Citi
Fuji
Accenture
Cipla
McKinsey
Baxter
Fish and Richardson

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: RE41393

« Back to Dashboard

Which drugs does patent RE41393 protect, and when does it expire?

Patent RE41393 protects IXEMPRA KIT and is included in one NDA.

Protection for IXEMPRA KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: RE41393
Title:Treatment of refractory tumors using epothilone derivatives
Abstract:Methods of treating tumors in a mammal, especially a human that has demonstrated resistance to other chemotherapeutic agents, is disclosed. Specifically, methods of the present invention are effective in tumors that have initially been unresponsive to taxane therapy, or have developed resistance during the course of treatment. The methods of the present invention comprise administering epothilone derivatives selected from those represented by the formula: ##STR00001## The subject epothilone derivatives are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncology agents in that they are efficacious upon oral administration.
Inventor(s): Lee; Francis Y.F. (Yardley, PA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:11/346,579
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent RE41393

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;IV (INFUSION) 022065-001 Oct 16, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
R-pharm Us Llc IXEMPRA KIT ixabepilone INJECTABLE;IV (INFUSION) 022065-002 Oct 16, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Queensland Health
Fish and Richardson
Dow
Accenture
Harvard Business School
QuintilesIMS
Fuji
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot